Clinical trials: Central Line Complication, open to volunteers
Kidney Failure, Chronic, Kidney Transplantation
Drone Transport of Deceased-Donor Kidney Grafts Between Two French Hospitals Before Transplantation: a Pilot Safety Study
Cold ischemia time, the period during which a donated kidney is kept cold outside the body between its removal from the donor and its transplantation into the recipient, is one of the main modifiable factors influencing how…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Delayed Graft Function, Cold Ischemia
- Trial name
- RAfALREIN (NCT07851571)
- Testing
- Kidney graft transport by autonomous unmanned aircraft (drone) between the procurement and transplantation centres
- Volunteers
- 5 people
- Sponsor
- Nantes University Hospital
Surveillance, Endoscopy
"Airway Complications in Pediatric Patients With Tracheostomies: To What Extent Can Symptoms Identified by Caregivers or Pediatricians Serve as Predictors for Airway Complications Confirmed Through Surveillance Endoscopy?"
Study Objective: This observational study aims to prospectively investigate to what extent tracheostomy-related complications in children are asymptomatic or associated with symptoms when detected through surveillance airway…
- Conditions
- Surveillance, Endoscopy, Tracheostomy Complication, Tracheostomy Complications
- Trial name
- NCT07121517
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Karolinska Institutet
Central Venous Catheters, Catheter Complications
Complications Associated With Multiple Central Venous Accesses in the Internal Jugular Vein
Patients at risk of significant intraoperative blood loss and/or potential hemodynamic instability often necessitate the placement of two or more central venous catheters, including large bore catheters.
- Conditions
- Central Venous Catheters, Catheter Complications, Catheter Related Complication
- Trial name
- NCT06466226
- Testing
- Multiple central venous lines in two sites separately, Multiple central venous lines in one site (internal jugular vein)
- Volunteers
- 156 people
- Sponsor
- Hospital Nossa Senhora da Conceicao
Peripherally Inserted Central Catheter, Umbilical Venous Catheter
Umbilical Venous Versus Peripherally Inserted Central Catheters in Neonates: A Prospective Cohort Study of Complications, Catheter Survival, and CLABSI"
This study aims to prospectively compare umbilical venous catheters (UVCs) and peripherally inserted central catheters (PICCs) in neonates, focusing on complications, catheter survival, and central line-associated bloodstream…
- Conditions
- Peripherally Inserted Central Catheter, Umbilical Venous Catheter, CLABSI - Central Line Associated Bloodstream Infection
- Trial name
- NCT07209670
- Testing
- peripherally inserted central catheter insertion, umbilical venous catheters insertion
- Volunteers
- 360 people
- Sponsor
- Assiut University
Device Related Infection, Vascular Access Complication
The IVCare Adaptive Platform Trial
The IVCare trial is a multicentre adaptive platform study evaluating interventions to prevent infections and other complications associated with central venous access devices (CVADs) in patients with newly inserted or existing…
- Conditions
- Device Related Infection, Vascular Access Complication, Device Related Sepsis, Catheter Infection
- Trial name
- NCT07587593
- Testing
- Connectors/Caps Domain - Standard of Care, Curos™, ClearGuard™ HD
- Volunteers
- 2,500 people
- Sponsor
- The University of Queensland
Ovarian Cancer, HGSOC
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer.
- Conditions
- Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Trial name
- OVACT (NCT07665515)
- Testing
- CryptiVax-1001
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Epitopea Ltd
Ovarian Cancer
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
The purpose of this study is to identify the genetic characteristic(s), specifically degree of African ancestry, and environmental characteristic(s) that appear to be related to the effects, both good and bad, that the…
- Trial name
- NCT06412120
- Testing
- Niraparib
- Where
- 4 sites in United States, Nigeria
- Volunteers
- 70 people
- Sponsor
- University of Miami
Anticoagulant-induced Bleeding, Direct Oral Anticoagulant
Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study
The peri-procedural management of direct oral anticoagulants (DOACs) in persons with cancer (PWC) undergoing tunneled or port central venous catheter (CVC) insertion is a common but understudied clinical problem, with conflicting…
- Conditions
- Anticoagulant-induced Bleeding, Direct Oral Anticoagulant, Cancer, Central Venous Catheter
- Trial name
- VENO CAT (NCT06887270)
- Testing
- Continued DOAC, Interrupted DOAC
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Neonatal Infection
Impact of a Multi-infusion Strategy in Neonatology on the Rate of Central Line-associated Bloodstream Infections
The management of premature infants hospitalized in neonatal units requires the simultaneous intravenous (IV) infusion of several drugs and parenteral nutrition solutions, when oral administration is impossible or unsuitable.
- Trial name
- EDELVAISS (NCT06656104)
- Testing
- Reference strategy, Experimental strategy
- Where
- 3 sites in France
- Volunteers
- 569 people
- Sponsor
- Hospices Civils de Lyon
Endometrial Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.
- Trial name
- TroFuse-033 (NCT06952504)
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 268 sites in United States, Argentina and 32 more
- Volunteers
- 1,123 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreas Cancer, Lung Cancer
Stereotactic Magnetic Resonance Guided Radiation Therapy
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
- Conditions
- Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases
- Trial name
- NCT04115254
- Testing
- MR-guided Linac
- Where
- 2 sites in United States
- Volunteers
- 397 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Neoplasms, Ovarian Cancer
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Trial name
- TroFuse-021 (NCT07318558)
- Testing
- Sacituzumab tirumotecan, Bevacizumab, Rescue Medications
- Where
- 167 sites in United States, Argentina and 28 more
- Volunteers
- 900 people
- Sponsor
- Merck Sharp & Dohme LLC
Vascular Access Complication, Device Related Infection
Chlorhexidine Caps for CLABSI Prevention in Hemodialysis: a Pilot Randomized Controlled Trial
The goal of this clinical trial is to compare a chlorhexidine antimicrobial barrier cap in patients requiring hemodialysis treatment to the standard hemodialysis caps currently used within the Metro North Kidney Health Service.
- Conditions
- Vascular Access Complication, Device Related Infection, Device Related Sepsis, Catheter Infection
- Trial name
- ECHO-HD (NCT07019610)
- Testing
- ClearGuard HD, B Braun Combi-stopper
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- The University of Queensland
Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06824467
- Testing
- Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist
- Where
- 198 sites in United States, Argentina and 27 more
- Volunteers
- 770 people
- Sponsor
- Merck Sharp & Dohme LLC
Intensive Care (ICU), Central Venous Catheter Related Infections
Impact of Infusion Line Change Frequency on Infectious Complications Related to Central Venous Catheters in the ICU - A Randomized Controlled Trial
In the intensive care unit, patients' care and secure drugs administration require a central venous catheter. These invasive devices can lead to complications, particularly infections.
- Conditions
- Intensive Care (ICU), Central Venous Catheter Related Infections, Critical Care Nursing, Catheter-associated Bloodstream Infections (CLABSI)
- Trial name
- TANDOORI (NCT07183592)
- Testing
- 7-day Infusion set replacement, 4-day infusion set replacement
- Where
- 27 sites in France
- Volunteers
- 2,830 people
- Sponsor
- University Hospital, Angers
Ovarian Cancer
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP…
- Trial name
- NCT06954584
- Testing
- Bevacizumab, Fluzoparib Monotherapy, Dietary Intervention
- Where
- 2 sites in China
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Cervical Cancer Stage IVB
A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The study medications were used as follows: 1 cycle every 21 days (3 weeks) of the following regimen. Test drug: QL1706, HPV 9-valent vaccine QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on Day 1 of each…
- Trial name
- QL1706 (NCT06882447)
- Testing
- Trial drug: QL1706, HPV 9-valent vaccine
- Volunteers
- 35 people
- Sponsor
- Northern Jiangsu People's Hospital
Ovarian Cancer
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)
This is an interventional trial. The goal of this clinical trial is dose finding. There are two phases: phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with…
- Trial name
- NICHOL (NCT06594679)
- Testing
- Niraparib Tosylate Monohydrate
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
【Treatment of Urothelial Carcinoma】 Treatment for urothelial carcinoma includes surgery, chemotherapy (anticancer drugs), and radiation therapy.
- Conditions
- Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra, Urothelial Carcinoma Recurrent
- Trial name
- GRAPE (NCT06983210)
- Testing
- Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy
- Where
- Japan
- Volunteers
- 43 people
- Sponsor
- Nagoya University
Neoplasms, Endometrial
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer
This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).
- Trial name
- NCT07652515
- Testing
- Dostarlimab, Carboplatin, Paclitaxel
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline